Impact of TOP2A Deletion on Breast Cancer Prognosis
Author Information
Author(s): Usha Lydia, Tabesh Bita, Morrison Larry E, Rao Ruta D, Jacobson Kris, Zhu April, Basu Sanjib, Coon John S
Primary Institution: Rush University
Hypothesis
The study investigates the prognostic significance of TOP2A gene copy loss in ERBB2-amplified breast cancer.
Conclusion
TOP2A deletion is associated with poor prognosis in ERBB2-amplified breast carcinomas.
Supporting Evidence
- 67% of cases with TOP2A deletion had recurrence, compared to 12% in other classes.
- TOP2A deletion was significantly associated with time to recurrence.
- TOP2A deletion had a strong association with unfavorable clinical outcomes.
Takeaway
If a specific gene called TOP2A is missing in breast cancer patients, it can mean their cancer is more likely to come back.
Methodology
The study analyzed archival tissue samples from 63 breast cancer patients with ERBB2 amplification using FISH probes.
Potential Biases
The small sample size may limit the generalizability of the findings.
Limitations
The study is based on a small number of highly selected patients with relatively short follow-up.
Participant Demographics
Patients with ERBB2-amplified breast cancer treated at Rush University Medical Center.
Statistical Information
P-Value
0.004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website